Altieri DC . The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609–615. ArticleCASPubMed Google Scholar
Liston P, Fong WG, Korneluk RG . The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22: 8568–8580. ArticleCASPubMed Google Scholar
Altieri DC . Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46–54. ArticleCASPubMed Google Scholar
Chen-Kiang S . Cell-cycle control of plasma cell differentiation and tumorigenesis. Immunol Rev 2003; 194: 39–47. ArticleCASPubMed Google Scholar
Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745–1757. ArticleCASPubMed Google Scholar
Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004; 104: 1120–1126. ArticleCASPubMed Google Scholar
Magrangeas F, Lode L, Wuilleme S, Minvielle S, Avet-Loiseau H . Genetic heterogeneity in multiple myeloma. Leukemia 2005; 19: 191–194. ArticleCASPubMed Google Scholar
Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006; 107: 3669–3675. ArticleCASPubMedPubMed Central Google Scholar
Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100: 194–199. ArticleCASPubMed Google Scholar
Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM et al. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005; 106: 4330–4338. ArticleCASPubMed Google Scholar
Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006; 107: 669–678. ArticlePubMed Google Scholar
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99: 4079–4086. ArticleCASPubMed Google Scholar
Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P et al. The phenotype of normal, reactive and malignant plasma cells. Identification of ‘many and multiple myelomas’ and of new targets for myeloma therapy. Hematologica 2006; 91: 1234–1240. CAS Google Scholar
Barille S, Bataille R, Rapp MJ, Harousseau JL, Amiot M . Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. J Immunol 1999; 163: 5723–5728. CASPubMed Google Scholar
Jego G, Bataille R, Pellat-Deceunynck C . Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001; 97: 1817–1822. ArticleCASPubMed Google Scholar
Brummelkamp TR, Bernards R, Agami R . A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550–553. ArticleCASPubMed Google Scholar
Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP . Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003; 116: 2987–2998. ArticleCASPubMed Google Scholar
Qin XF, An DS, Chen IS, Baltimore D . Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183–188. ArticleCASPubMed Google Scholar
Li F, Altieri DC . Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344 (Part 2): 305–311. CASPubMedPubMed Central Google Scholar
Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94: 522–528. ArticleCASPubMed Google Scholar
Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12: 11–19. ArticleCASPubMed Google Scholar
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247–3257. ArticleCASPubMed Google Scholar
Li F, Yang J, Ramnath N, Javle MM, Tan D . Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005; 114: 509–512. ArticleCASPubMedPubMed Central Google Scholar
Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921–1925. CASPubMed Google Scholar
Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164: 501–510. ArticleCASPubMedPubMed Central Google Scholar
Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111: 196–203. ArticleCASPubMed Google Scholar
Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Haematol 2006; 81: 824–831. ArticleCAS Google Scholar
Conway EM, Pollefeyt S, Steiner-Mosonyi M, Luo W, Devriese A, Lupu F et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology 2002; 123: 619–631. ArticleCASPubMed Google Scholar
Salvesen GS, Duckett CS . IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401–410. ArticleCASPubMed Google Scholar
Song Z, Yao X, Wu M . Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278: 23130–23140. ArticleCASPubMed Google Scholar
Liu T, Brouha B, Grossman D . Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004; 23: 39–48. ArticleCASPubMedPubMed Central Google Scholar
Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC . Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117–1127. ArticleCASPubMedPubMed Central Google Scholar
Grossman D, Kim PJ, Schechner JS, Altieri DC . Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98: 635–640. ArticleCASPubMedPubMed Central Google Scholar
Fukuda S, Pelus LM . Elevation of Survivin levels by hematopoietic growth factors occurs in quiescent CD34+ hematopoietic stem and progenitor cells before cell cycle entry. Cell Cycle 2002; 1: 322–326. ArticleCASPubMed Google Scholar
Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000; 19: 3225–3234. ArticleCASPubMed Google Scholar
Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7: 1015–1018. CASPubMed Google Scholar
Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC . Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2004; 279: 2077–2084. ArticleCASPubMed Google Scholar
Yang D, Welm A, Bishop JM . Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004; 101: 15100–15105. ArticleCASPubMedPubMed Central Google Scholar